Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rodero, L.
Right arrow Articles by Guelfand, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodero, L.
Right arrow Articles by Guelfand, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 239-242
© 2000 The British Society for Antimicrobial Chemotherapy

Brief reports

In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy

L. Roderoa,*, S. Córdobaa, P. Cahnb, F. Hochenfellnera, G. Davela, C. Canterosa, S. Kaufmanb and L. Guelfandb

a Departamento Micología, Instituto Nacional de Enfermedades Infecciosas, ANLIS ‘Dr Carlos G. Malbrán’, Av. Velez Sarsfield 563, 1281 Buenos Aires; b Hospital J. A. Fernandez, Buenos Aires, Argentina

The in vitro activities of three antifungal drugs alone and in combination were evaluated against five isolates of Cryptococcus neoformans using time–kill curves (TKC). The isolates were from AIDS patients who had either died or had failed to show a clinical response during amphotericin B (AMB) treatment. AMB, fluconazole (FCZ) and flucytosine (5FC), and combinations of the drugs (AMB plus 5FC, AMB plus rifampicin (RIF) and FCZ plus 5FC), were evaluated. With all five isolates AMB did not show fungicidal activity; instead, a persistent or tolerant effect was observed. Combinations of AMB plus 5FC and AMB plus RIF showed a clear synergic effect, except for one isolate tested with AMB plus RIF. In contrast, the FCZ plus 5FC combination did not inhibit growth of any isolate.

* Corresponding author. Tel/Fax: +54-11-4302-5066; E-mail: lrodero{at}mail.retina.ar


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
E. Dannaoui, M. Abdul, M. Arpin, A. Michel-Nguyen, M. A. Piens, A. Favel, O. Lortholary, F. Dromer, and the French Cryptococcosis Study Group
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2464 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Cuenca-Estrella
Combinations of antifungal agents in therapy-what value are they?
J. Antimicrob. Chemother., November 1, 2004; 54(5): 854 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Schwarz, F. Dromer, O. Lortholary, and E. Dannaoui
In Vitro Interaction of Flucytosine with Conventional and New Antifungals against Cryptococcus neoformans Clinical Isolates
Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3361 - 3364.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Dannaoui, J. Afeltra, J. F. G. M. Meis, and P. E. Verweij
In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2708 - 2711.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. H. Rex, M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, et al.
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Clin. Microbiol. Rev., October 1, 2001; 14(4): 643 - 658.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.